DCT
1:21-cv-01807
Harbour Antibodies BV v. Teneobio Inc
Key Events
Amended Complaint
Table of Contents
complaint Intelligence
I. Executive Summary and Procedural Information
- Parties & Counsel:
- Plaintiff: Harbour Antibodies BV, Harbour Antibodies HCAb BV, Erasmus University Medical Center Rotterdam, and Dr. Roger Kingdon Craig (Netherlands, United Kingdom)
- Defendant: Teneobio, Inc. and Amgen, Inc. (Delaware)
- Plaintiff's Counsel: Potter Anderson & Corroon LLP
- Case Identification: 1:21-cv-01807, D. Del., 02/04/2025
- Venue Allegations: Venue is alleged to be proper in the District of Delaware because both Defendants are incorporated in the State of Delaware.
- Core Dispute: Plaintiffs allege that Defendants' UniRat® transgenic rodent platform, used for developing heavy chain-only antibodies, infringes four U.S. patents covering methods for producing such antibodies in genetically engineered animals.
- Technical Context: The technology involves creating fully human heavy chain-only antibodies (HCAbs) in transgenic animals, a platform technology with significant applications in developing next-generation therapeutic and diagnostic molecules.
- Key Procedural History: The complaint alleges that Defendant Amgen had prior knowledge of the asserted technology through an "HCab License Agreement" with Plaintiff HBAB, which was effective December 8, 2011, and terminated by Amgen in November 2017. The complaint also alleges that Plaintiffs, through counsel, contacted Defendant Teneobio's CEO on October 6, 2017, to discuss infringement of the '877 and '179 patents, but Teneobio refused to engage in licensing discussions.
Case Timeline
| Date | Event |
|---|---|
| 2004-07-22 | Priority Date for '877, '179, and '970 Patents |
| 2011-12-08 | Effective date of HCab License Agreement between Amgen and HBAB |
| 2015-01-01 | (Approx.) Teneobio pivots to HCAb technology |
| 2015-03-13 | Priority Date for '420 Patent |
| 2016-05-24 | U.S. Patent No. 9,346,877 Issues |
| 2016-05-31 | U.S. Patent No. 9,353,179 Issues |
| 2017-10-06 | Plaintiffs first contact Teneobio regarding infringement |
| 2017-11-01 | Amgen terminates HCab License Agreement |
| 2018-03-08 | Teneobio's counsel responds to Plaintiffs, rejecting license discussions |
| 2021-02-02 | U.S. Patent No. 10,906,970 Issues |
| 2021-05-04 | U.S. Patent No. 10,993,420 Issues |
| 2021-10-19 | Amgen announces completion of Teneobio acquisition |
| 2025-02-04 | First Amended Complaint Filed |
II. Technology and Patent(s)-in-Suit Analysis
U.S. Patent No. 9,346,877 - "Binding Molecules"
The Invention Explained
- Problem Addressed: Naturally occurring human antibodies are composed of heavy and light chains; a heavy chain alone is prone to aggregation and is not properly secreted from a cell (Compl. ¶42). This instability made it difficult to develop therapeutics based on smaller, heavy chain-only formats (Compl. ¶47).
- The Patented Solution: The invention provides a method to produce soluble, antigen-specific heavy chain variable domains (V(H) domains) by using a transgenic rodent (Compl. ¶71). The rodent is genetically engineered to have a "heterologous VH heavy chain locus" that contains the genetic segments needed to form a variable domain (VH, D, and J segments) but is specifically designed to lack the CH1 domain, which is responsible for binding the light chain (Compl. ¶71(a)(ii)). Upon immunization, this rodent produces soluble heavy chain-only antibodies, from which the V(H) binding domains can be cloned and produced (Compl. ¶71(b); Compl. ¶71(c); '877 Patent, col. 5:1-6:11).
- Technical Importance: This method enabled the in vivo generation and affinity maturation of fully human, heavy chain-only antibody domains, providing a platform for developing stable, high-affinity therapeutic molecules that were previously difficult to produce (Compl. ¶55).
Key Claims at a Glance
- The complaint asserts infringement of at least Claim 1 of the '877 Patent (Compl. ¶70).
- Claim 1 of the '877 Patent contains the following essential elements:
- A method comprising the steps of immunising a transgenic rodent that expresses a heterologous V(H) heavy chain locus.
- The locus must comprise at least one V(H), at least five D, and at least one J gene segment, plus a constant region.
- The constant region must not encode a functional CH1 domain.
- The V(H), D, and J gene segments must be capable of recombining to form a VDJ coding sequence.
- The recombined locus, upon antigen challenge, must be capable of forming a soluble, heavy chain-only antibody.
- Cloning the V(H) locus from an antibody-producing cell of the rodent after affinity maturation.
- Producing the soluble, V(H) binding domain from the cloned locus.
- The complaint does not explicitly reserve the right to assert dependent claims for this patent.
U.S. Patent No. 9,353,179 - "Binding Molecules"
The Invention Explained
- Problem Addressed: As with the '877 Patent, the invention addresses the difficulty of producing stable, functional heavy chain-only antibodies (HCAbs), which naturally tend to aggregate in the absence of a light chain partner (Compl. ¶42).
- The Patented Solution: The '179 Patent claims a method for producing the entire soluble, antigen-specific heavy chain-only antibody, rather than just the binding domain as in the '877 Patent (Compl. ¶84). The method uses a transgenic rodent engineered with a heterologous heavy chain locus that lacks a functional CH1 domain, which is immunized with an antigen to generate the desired HCAbs (Compl. ¶84(a)). The method includes cloning the antibody from a producing cell after affinity maturation and then producing the soluble antibody from that clone (Compl. ¶84(b); Compl. ¶84(c); '179 Patent, abstract).
- Technical Importance: The invention provides a complete method for discovering and producing entire fully human HCAbs, which are therapeutically valuable due to their small size, stability, and high antigen-binding affinity (Compl. ¶¶46, 55).
Key Claims at a Glance
- The complaint asserts infringement of at least Claim 1 of the '179 Patent (Compl. ¶83).
- Claim 1 of the '179 Patent contains the following essential elements:
- A method for producing soluble, antigen-specific heavy chain only antibodies, comprising immunising a transgenic rodent expressing a heterologous V(H) heavy chain locus.
- The locus must comprise at least one V(H), at least five D, and at least one J gene segment, plus a constant region.
- The constant region must not encode a functional CH1 domain.
- The V(H), D, and J segments must be capable of recombining.
- The recombined locus, upon antigen challenge, must be capable of forming a soluble, heavy chain-only antibody.
- Cloning a soluble heavy chain only antibody from an antibody-producing cell of the rodent after affinity maturation.
- Producing the soluble, antigen-specific heavy chain only antibody from the clone.
- The complaint does not explicitly reserve the right to assert dependent claims for this patent.
U.S. Patent No. 10,906,970 - "Methods of Making Heavy Chain Only Antibodies Using Transgenic Animals"
- Technology Synopsis: The '970 Patent protects a method for producing soluble HCAbs by immunizing a transgenic rodent engineered with a heterologous heavy chain locus ('970 Patent, abstract). A distinguishing feature of the invention is the specific requirement that the variable region of the locus comprises "from 20 to 40 D gene segments" ('970 Patent, claim 1). This genetic diversity in the D region is intended to enhance the antibody repertoire generated by the animal.
- Asserted Claims: At least Claim 1 (Compl. ¶96).
- Accused Features: The UniRat® platform is accused of infringing, with the complaint alleging that the platform's immunoglobulin locus is made up of "two to 40 D gene segments" (Compl. ¶100(c)).
U.S. Patent No. 10,993,420 - "Production of Heavy Chain Only Antibodies in Transgenic Mammals"
- Technology Synopsis: The '420 Patent claims a method for producing a V(H) heavy chain-only antibody in a transgenic rat or mouse ('420 Patent, claim 1). The method requires expressing a transgene that contains specific human V(H) gene segments (including at least one of VH3-66 or VH3-9), does not comprise all subclasses of human V(H) genes, and lacks a CH1 domain. A critical element is the silencing of the rodent's endogenous heavy and light chain loci to ensure production is focused on the desired transgenic antibody ('420 Patent, claim 1).
- Asserted Claims: At least Claim 1 (Compl. ¶109).
- Accused Features: The UniRat® platform is accused of infringing, specifically alleging the use of transgenic rats whose endogenous immunoglobulin loci have been silenced and that express specific required human V(H)3 gene segments, including VH3-9 and VH3-66 (Compl. ¶113(g); Compl. ¶113(k)).
III. The Accused Instrumentality
Product Identification
- The accused instrumentalities are Defendants' "Accused Methods and Products," which include the UniRat® discovery platform and various derived antibody products such as UniAb™, UniDab™, TNB-383B, TNB-486, and TNB-585 (Compl. ¶70).
Functionality and Market Context
- The UniRat® platform is described as a technology that uses "genetically engineered rats expressing heavy chain only antibodies" to generate therapeutic molecules (Compl. ¶74(b)). These rats are engineered with a "recombinant heavy chain-only immunoglobulin (Ig) locus" that contains human V(H), D, and J gene segments but is linked to rat constant regions that have been modified to lack the CH1 domain (Compl. ¶74(c); Compl. ¶74(d)). The platform is based on immunizing these rats to produce "high affinity antigen-specific heavy chain only antibodies" (Compl. ¶74(a)).
- The complaint alleges the platform is a significant commercial asset, noting that Amgen acquired Teneobio and the UniRat® platform for over $2.5 billion (Compl. ¶4). It further alleges that Defendants have licensed the platform to third parties for antibody production (Compl. ¶61).
IV. Analysis of Infringement Allegations
U.S. Patent No. 9,346,877 Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| A method for the production of soluble, antigen-specific V(H) binding domain comprising: (a) immunising a transgenic rodent expressing a heterologous V(H) heavy chain locus with an antigen wherein: | The UniRat® platform is based on the immunization of transgenic rats to produce antigen-specific heavy chain only antibodies, which contain V(H) binding domains. | ¶74(a); ¶74(b) | col. 13:14-19 |
| (i) the V(H) heavy chain locus comprises a variable region comprising at least one V(H) gene segment, at least five D gene segment, at least one J gene segment and at least one heavy chain constant region; | The UniRat® platform's locus allegedly comprises human V, D, and J gene segments, including "two to 40 D gene segments." | ¶74(c) | col. 11:1-4 |
| (ii) each constant region does not encode a functional C(H)1 domain; | The UniRat® platform allegedly uses rat constant regions that are "deleted for CH1" or have "lacking CH1 domains." | ¶74(d) | col. 12:47-51 |
| (iii) a V(H) gene segment, a D gene segment and a J gene segment are capable of recombining to form a VDJ coding sequence; | The V gene segment of the UniRat® is alleged to be capable of recombining with D and J segments to generate a heavy chain-only antibody. | ¶74(e) | col. 12:28-31 |
| (iv) the recombined V(H) heavy chain locus, when expressed upon antigen challenge, is capable of forming a soluble, heavy chain-only antibody...; | The UniRat® platform is alleged to result in the production of "high affinity antigen-specific heavy chain only antibodies." | ¶74(f) | col. 12:32-40 |
| (b) cloning a V(H) locus resulting from recombination...from an antibody-producing cell of said immunised transgenic rodent after affinity maturation via somatic mutation; and | The UniRat® discovery platform allegedly clones the V(H) heavy chain locus after affinity maturation. | ¶74(g) | col. 13:46-51 |
| (c) producing said soluble, V(H) binding domain from the clone of step (b). | The UniRat® platform is alleged to produce heavy chain only antibodies, which include soluble V(H) binding domains, via expression in a host. | ¶74(h) | col. 14:12-21 |
U.S. Patent No. 9,353,179 Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| A method for the production of soluble, antigen-specific heavy chain only antibodies comprising: (a) immunising a transgenic rodent expressing a heterologous V(H) heavy chain locus with an antigen wherein: | The UniRat® platform is based on the immunization of transgenic rats to produce soluble, antigen-specific heavy chain only antibodies. | ¶87(a); ¶87(b) | col. 13:14-19 |
| (i) the V(H) heavy chain locus comprises a variable region comprising at least one V(H) gene segment, at least five D gene segments, at least one J gene segment and at least one heavy chain constant region; | The UniRat® platform's locus allegedly comprises human V, D, and J gene segments, including "two to 40 D gene segments." | ¶87(c) | col. 11:1-4 |
| (ii) each constant region does not encode a functional C(H)1 domain; | The UniRat® platform allegedly uses rat constant regions with CH1 domains deleted. | ¶87(d) | col. 12:47-51 |
| (iv) the recombined V(H) heavy chain locus, when expressed upon antigen challenge, is capable of forming a soluble, heavy chain-only antibody...; | The UniRat® platform is alleged to be capable of producing soluble, "high affinity antigen-specific heavy chain only antibodies." | ¶87(f) | col. 12:32-40 |
| (b) cloning a soluble heavy chain only antibody from an antibody-producing cell of said immunised transgenic rodent after affinity maturation via somatic mutation; and | The UniRat® platform is alleged to clone the heavy chain locus after affinity maturation and produce antibodies via recombinant DNA technology. | ¶87(g) | col. 13:46-51 |
| (c) producing said soluble, antigen specific heavy chain only antibody from the clone of step (b). | The UniRat® platform is alleged to produce soluble, heavy chain only antibodies from the cloned locus. | ¶87(h) | col. 14:12-21 |
- Identified Points of Contention:
- Scope Questions: A central question for the '877 and '179 Patents may be the scope of "at least five D gene segments." The complaint alleges the accused UniRat® platform uses "two to 40 D gene segments" (Compl. ¶74(c)). While this range overlaps with the claim limitation, it raises the factual question of whether Defendants' actual practice ever falls below the "five D gene segment" floor, which could be a basis for a non-infringement argument for specific products or methods.
- Technical Questions: A key technical question will be whether the accused UniRat® platform's constant region truly "does not encode a functional C(H)1 domain" as required by the claims. While the complaint alleges the CH1 domain is "deleted" or "lacking" (Compl. ¶74(d)), the precise genetic makeup of the accused construct and any residual, non-coding sequences could become a point of contention regarding the term "functional."
- The complaint provides a figure depicting the genetic maps of two UniRat® strains, HC27 and HC31, to support infringement allegations for the '420 Patent. This visual evidence shows the specific human V genes, including the required VH3-9 and VH3-66 segments, incorporated into the rat genome (Compl. p. 42, Fig. 1A-B).
V. Key Claim Terms for Construction
The Term: "functional C(H)1 domain"
Context and Importance: This term is the technological linchpin of the asserted patents. The invention's core concept is the elimination of this domain's function to enable the production of soluble heavy chain-only antibodies. The entire infringement analysis for all four patents hinges on whether the accused UniRat® platform's genetic construct contains a "functional C(H)1 domain."
Intrinsic Evidence for Interpretation:
- Evidence for a Broader Interpretation: The patents consistently define the purpose of the CH1 domain as binding to the light chain. A broad interpretation, which may be advanced by Plaintiffs, would suggest that any construct that is incapable of stably associating with an immunoglobulin light chain lacks a "functional" CH1 domain, regardless of its specific sequence.
- Evidence for a Narrower Interpretation: The patents state that the absence of a functional CH1 domain renders the heavy chain "unable to associate with an immunoglobulin light chain" ('877 Patent, col. 4:43-45). Practitioners may focus on the word "functional," as Defendants could argue that even if their construct has a deleted or modified CH1 region, any residual, non-obvious binding affinity for a light chain, however weak, means the domain is not completely non-functional, thereby avoiding literal infringement.
The Term: "soluble"
Context and Importance: The patents aim to solve the problem of heavy chain aggregation by producing "soluble" antibodies. Infringement requires that the antibodies produced by the UniRat® platform are, in fact, "soluble." This term's definition will be critical in determining if the accused products meet this key claim limitation.
Intrinsic Evidence for Interpretation:
- Evidence for a Broader Interpretation: The specification provides a general definition, stating a soluble V(H) domain "remains in solution and is active in a physiological medium without the need for any other factor to maintain solubility" ('877 Patent, col. 11:41-44). This could support a broad, qualitative understanding of the term.
- Evidence for a Narrower Interpretation: Defendants may argue that "soluble" should be construed more narrowly, potentially tied to specific biophysical properties like resistance to aggregation or a specific expression yield mentioned in the patent's examples. The patent's emphasis on solving the aggregation problem suggests "soluble" implies a significant and measurable improvement in this property, which could become a quantitative battle of expert evidence.
VI. Other Allegations
- Indirect Infringement: The complaint alleges inducement of infringement, stating Defendants knowingly encourage customers to use the Accused Methods and Products by "offering the UniRat® discovery platform" and providing instructions (Compl. ¶75; Compl. ¶88). It also alleges contributory infringement on the basis that the UniRat® platform is a material part of the invention, is especially made to practice the invention, and is not a staple article of commerce with substantial non-infringing uses (Compl. ¶77; Compl. ¶90).
- Willful Infringement: Willfulness is alleged based on pre-suit knowledge. For Defendant Teneobio, knowledge is alleged since at least October 6, 2017, based on a notice letter from Plaintiffs' counsel (Compl. ¶78; Compl. ¶64). For Defendant Amgen, knowledge is alleged since 2016 based on a prior license agreement for related technology and, at a minimum, upon its acquisition of Teneobio in October 2021 (Compl. ¶78; Compl. ¶67).
VII. Analyst's Conclusion: Key Questions for the Case
- A core issue will be one of claim scope and construction, particularly for the more recent patents. For the '970 Patent, the case may turn on whether the accused UniRat® platform's alleged "two to 40 D gene segments" falls within the claimed range of "from 20 to 40 D gene segments." For the '420 Patent, a key factual question will be whether Defendants' UniRat® strains express the specifically claimed V(H)3 gene segments, an allegation Plaintiffs support with visual evidence from a technical publication.
- A second central question will be the definition of functionality: how "non-functional" must a CH1 domain be to fall outside the patent claims? The case will likely involve a technical dispute over whether the genetic modifications in the accused UniRat® platform completely eliminate the CH1 domain's function of binding to a light chain, or if any residual structure or minimal affinity is sufficient to escape infringement.
- Finally, the extensive allegations of pre-suit knowledge, including a prior licensing relationship with Amgen and a specific notice letter to Teneobio, raise a significant question of willfulness. A key part of the case will likely be the court's examination of Defendants' conduct after being made aware of the patents and whether it was objectively reckless.
Analysis metadata
Loading Amended Complaint
Suggested improvements